文献速递肺结节与肺癌

信迪利单抗联合化疗用于EGFR突变非鳞NSCLC进展后患者的ORIENT-31第二次期中分析

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2023-05-05

总生存数据尚不成熟,安全性总体可控。

要点

  • 三药组≥3级治疗相关不良事件发生率为56%,需关注安全性管理。

核心结论

  • 信迪利单抗联合化疗较单纯化疗显著改善EGFR-TKI治疗后进展的EGFR突变非鳞NSCLC患者的PFS。
  • 信迪利单抗联合IBI305及化疗组的PFS获益在第二次期中分析中持续存在。

研究设计与样本

  • 双盲、随机、安慰剂对照、3期试验,在中国52个中心进行。
  • 纳入476例18-75岁、EGFR突变非鳞NSCLC、EGFR-TKI治疗后进展的患者,按1:1:1随机分配。
  • 三组分别接受信迪利单抗+IBI305+化疗、信迪利单抗+化疗或单纯化疗,每3周一次,共4周期后维持治疗。
  • 主要终点为独立影像评审委员会评估的意向治疗人群PFS。

主要发现

  • ≥3级治疗相关不良事件发生率:信迪利单抗+IBI305+化疗组56%(88/158),信迪利单抗+化疗组41%(64/156),单纯化疗组49%(79/160)。

关键数值与推荐

  • EGFR突变非鳞NSCLC患者,EGFR-TKI治疗后进展,至少有一个可测量病灶(RECIST 1.1)。
  • 信迪利单抗200 mg,IBI305 15 mg/kg,培美曲塞500 mg/m2,顺铂75 mg/m2,每3周第1天给药,共4周期。

临床怎么用

  • 对于EGFR-TKI治疗后进展的EGFR突变非鳞NSCLC患者,可考虑信迪利单抗联合培美曲塞和顺铂方案。
  • 信迪利单抗联合IBI305及化疗可作为可选方案,但需权衡PFS获益与安全性。
  • 治疗期间需监测≥3级不良事件,尤其是三药联合组。

局限性

  • 总生存数据尚未成熟,需更长随访。
  • 研究仅在中国进行,结果外推需谨慎。
  • 第二次期中分析为预设分析,但PFS获益的临床意义需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the first interim analysis of the ORIENT-31 trial, compared with chemotherapy alone, sintilimab plus bevacizumab biosimilar IBI305 plus chemotherapy (pemetrexed and cisplatin) significantly improved progression-free survival in patients with EGFR-mutated non-squamous non-small-cell lung cancer (NSCLC) who progressed on EGFR tyrosine-kinase inhibitor treatment. However, the benefit of anti-PD-1 or PD-L1 antibody added to chemotherapy in this patient population remains unclear, with no prospective evidence from phase 3 trials globally. We report the results from the prespecified second interim analysis of progression-free survival between sintilimab plus chemotherapy and chemotherapy alone, the updated results of sintilimab plus IBI305 plus chemotherapy, and preliminary overall survival results. METHODS: This double-blind, randomised, placebo-controlled, phase 3 trial was done at 52 centres across China and included patients aged 18-75 years with locally advanced or metastatic (stage IIIB, IIIC, or IV according to the American Joint Committee on Cancer, eighth edition) EGFR-mutated non-squamous NSCLC, disease progression after EGFR tyrosine-kinase inhibitor treatment (according to the Response Evaluation Criteria in Solid Tumours version 1.1 [RECIST 1.1]), and at least one measurable lesion (according to RECIST 1.1). Patients were randomly assigned (1:1:1), using an interactive web response system, to receive sintilimab (200 mg) plus IBI305 (15 mg/kg) plus pemetrexed (500 mg/m2) and cisplatin (75 mg/m2), sintilimab plus chemotherapy, or chemotherapy alone on day 1 of each 3-week cycle for four cycles, followed by maintenance therapy of sintilimab, IBI305, and pemetrexed. All study drugs were administered intravenously. The primary endpoint was progression-free survival in the intention-to-treat population assessed by an independent radiographic review committee. Data cutoff was March 31, 2022, unless otherwise specified. The study is registered at ClinicalTrials.gov, NCT03802240 (ongoing). FINDINGS: Between July 11, 2019, and March 31, 2022, 1011 patients were screened and 476 were randomly assigned (158 to the sintilimab plus IBI305 plus chemotherapy group, 158 to the sintilimab plus chemotherapy group, and 160 to the chemotherapy alone group). The median follow-up duration for progression-free survival was 12·9 months (IQR 8·2-17·8) in the sintilimab plus IBI305 plus chemotherapy group, 15·1 months (8·0-19·5) in the sintilimab plus chemotherapy group, and 14·4 months (9·8-23·8) in the chemotherapy alone group. Sintilimab plus chemotherapy significantly improved progression-free survival compared with chemotherapy alone (median 5·5 months [95% CI 4·5-6·1] vs 4·3 months [4·1-5·3]; hazard ratio [HR] 0·72 [95% CI 0·55-0·94]; two-sided p=0·016). Significant progression-free survival benefit was sustained with sintilimab plus IBI305 plus chemotherapy compared with chemotherapy alone (median 7·2 months [95% CI 6·6-9·3]; HR: 0·51 [0·39-0·67]; two-sided p<0·0001). As of data cutoff (July 4, 2022), the median overall survival was 21·1 months (95% CI 17·5-23·9) for sintilimab plus IBI305 plus chemotherapy (HR 0·98 [0·72-1·34]) and 20·5 months (15·8-25·3) for sintilimab plus chemotherapy group (HR 0·97 [0·71-1·32]) versus 19·2 months (15·8-22·4) for chemotherapy alone; after adjusting for crossover, the HR for sintilimab plus IBI305 plus chemotherapy to chemotherapy alone ranged from 0·79 (0·57-1·09) to 0·84 (0·61-1·15) and the HR for sintilimab plus chemotherapy to chemotherapy alone ranged from 0·78 (0·57-1·08) to 0·84 (0·61-1·16). The safety results were generally consistent with those in the first interim analysis; in particular, treatment-related adverse events of grade 3 or worse occurred in 88 (56%) of 158 patients in the sintilimab plus IBI305 plus chemotherapy group, 64 (41%) of 156 patients in the sintilimab plus chemotherapy group, and 79 (49%) of 160 patients in the chemotherapy alone group. INTERPRETATION: This is the first prospective phase 3 trial to show the benefit of anti-PD-1 antibody plus chemotherapy in patients with EGFR-mutated NSCLC who progressed on treatment with tyrosine-kinase inhibitors. Compared with chemotherapy alone, sintilimab combined with pemetrexed and cisplatin showed significant and clinically meaningful improvement of progression-free survival with an optimal safety profile. Sintilimab plus IBI305 plus chemotherapy continued to show progression-free survival benefit compared with chemotherapy alone in this second interim analysis with an additional 8-month follow-up. FUNDING: National Natural Science Foundation of China, Shanghai Municipal Science & Technology Commission Research Project, and Innovent Biologics. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Lu S, Wu L, Jian H, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2023. PMID: 37156249. doi:10.1016/S2213-2600(23)00135-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。